Table of Content

1 PD-1&PD-L1 Immunotherapy Market Overview
1.1 Product Overview and Scope of PD-1&PD-L1 Immunotherapy
1.2 PD-1&PD-L1 Immunotherapy Segment by Type
1.2.1 Global PD-1&PD-L1 Immunotherapy Market Value Comparison by Type (2024-2034)
1.2.2 PD-1 Inhibitors
1.2.3 PD-L1 Inhibitors
1.3 PD-1&PD-L1 Immunotherapy Segment by Application
1.3.1 Global PD-1&PD-L1 Immunotherapy Market Value by Application: (2024-2034)
1.3.2 Non-Small Cell Lung Cancer
1.3.3 Esophageal Cancer
1.3.4 Urothelial Carcinoma
1.3.5 Hepatocellular Carcinoma
1.3.6 Small Cell Lung Cancer
1.3.7 Others
1.4 Global PD-1&PD-L1 Immunotherapy Market Size Estimates and Forecasts
1.4.1 Global PD-1&PD-L1 Immunotherapy Revenue 2018-2034
1.4.2 Global PD-1&PD-L1 Immunotherapy Sales 2018-2034
1.4.3 Global PD-1&PD-L1 Immunotherapy Market Average Price (2018-2034)
1.5 Assumptions and Limitations
2 PD-1&PD-L1 Immunotherapy Market Competition by Manufacturers
2.1 Global PD-1&PD-L1 Immunotherapy Sales Market Share by Manufacturers (2018-2023)
2.2 Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Manufacturers (2018-2023)
2.3 Global PD-1&PD-L1 Immunotherapy Average Price by Manufacturers (2018-2023)
2.4 Global PD-1&PD-L1 Immunotherapy Industry Ranking 2021 VS 2024 VS 2023
2.5 Global Key Manufacturers of PD-1&PD-L1 Immunotherapy, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of PD-1&PD-L1 Immunotherapy, Product Type & Application
2.7 PD-1&PD-L1 Immunotherapy Market Competitive Situation and Trends
2.7.1 PD-1&PD-L1 Immunotherapy Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest PD-1&PD-L1 Immunotherapy Players Market Share by Revenue
2.7.3 Global PD-1&PD-L1 Immunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 PD-1&PD-L1 Immunotherapy Retrospective Market Scenario by Region
3.1 Global PD-1&PD-L1 Immunotherapy Market Size by Region: 2018 Versus 2024 Versus 2034
3.2 Global PD-1&PD-L1 Immunotherapy Global PD-1&PD-L1 Immunotherapy Sales by Region: 2018-2034
3.2.1 Global PD-1&PD-L1 Immunotherapy Sales by Region: 2018-2023
3.2.2 Global PD-1&PD-L1 Immunotherapy Sales by Region: 2024-2034
3.3 Global PD-1&PD-L1 Immunotherapy Global PD-1&PD-L1 Immunotherapy Revenue by Region: 2018-2034
3.3.1 Global PD-1&PD-L1 Immunotherapy Revenue by Region: 2018-2023
3.3.2 Global PD-1&PD-L1 Immunotherapy Revenue by Region: 2024-2034
3.4 North America PD-1&PD-L1 Immunotherapy Market Facts & Figures by Country
3.4.1 North America PD-1&PD-L1 Immunotherapy Market Size by Country: 2018 VS 2024 VS 2034
3.4.2 North America PD-1&PD-L1 Immunotherapy Sales by Country (2018-2034)
3.4.3 North America PD-1&PD-L1 Immunotherapy Revenue by Country (2018-2034)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe PD-1&PD-L1 Immunotherapy Market Facts & Figures by Country
3.5.1 Europe PD-1&PD-L1 Immunotherapy Market Size by Country: 2018 VS 2024 VS 2034
3.5.2 Europe PD-1&PD-L1 Immunotherapy Sales by Country (2018-2034)
3.5.3 Europe PD-1&PD-L1 Immunotherapy Revenue by Country (2018-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific PD-1&PD-L1 Immunotherapy Market Facts & Figures by Country
3.6.1 Asia Pacific PD-1&PD-L1 Immunotherapy Market Size by Country: 2018 VS 2024 VS 2034
3.6.2 Asia Pacific PD-1&PD-L1 Immunotherapy Sales by Country (2018-2034)
3.6.3 Asia Pacific PD-1&PD-L1 Immunotherapy Revenue by Country (2018-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America PD-1&PD-L1 Immunotherapy Market Facts & Figures by Country
3.7.1 Latin America PD-1&PD-L1 Immunotherapy Market Size by Country: 2018 VS 2024 VS 2034
3.7.2 Latin America PD-1&PD-L1 Immunotherapy Sales by Country (2018-2034)
3.7.3 Latin America PD-1&PD-L1 Immunotherapy Revenue by Country (2018-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa PD-1&PD-L1 Immunotherapy Market Facts & Figures by Country
3.8.1 Middle East and Africa PD-1&PD-L1 Immunotherapy Market Size by Country: 2018 VS 2024 VS 2034
3.8.2 Middle East and Africa PD-1&PD-L1 Immunotherapy Sales by Country (2018-2034)
3.8.3 Middle East and Africa PD-1&PD-L1 Immunotherapy Revenue by Country (2018-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global PD-1&PD-L1 Immunotherapy Sales by Type (2018-2034)
4.1.1 Global PD-1&PD-L1 Immunotherapy Sales by Type (2018-2023)
4.1.2 Global PD-1&PD-L1 Immunotherapy Sales by Type (2024-2034)
4.1.3 Global PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2018-2034)
4.2 Global PD-1&PD-L1 Immunotherapy Revenue by Type (2018-2034)
4.2.1 Global PD-1&PD-L1 Immunotherapy Revenue by Type (2018-2023)
4.2.2 Global PD-1&PD-L1 Immunotherapy Revenue by Type (2024-2034)
4.2.3 Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2018-2034)
4.3 Global PD-1&PD-L1 Immunotherapy Price by Type (2018-2034)
5 Segment by Application
5.1 Global PD-1&PD-L1 Immunotherapy Sales by Application (2018-2034)
5.1.1 Global PD-1&PD-L1 Immunotherapy Sales by Application (2018-2023)
5.1.2 Global PD-1&PD-L1 Immunotherapy Sales by Application (2024-2034)
5.1.3 Global PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2018-2034)
5.2 Global PD-1&PD-L1 Immunotherapy Revenue by Application (2018-2034)
5.2.1 Global PD-1&PD-L1 Immunotherapy Revenue by Application (2018-2023)
5.2.2 Global PD-1&PD-L1 Immunotherapy Revenue by Application (2024-2034)
5.2.3 Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Application (2018-2034)
5.3 Global PD-1&PD-L1 Immunotherapy Price by Application (2018-2034)
6 Key Companies Profiled
6.1 AstraZeneca Plc
6.1.1 AstraZeneca Plc Corporation Information
6.1.2 AstraZeneca Plc Description and Business Overview
6.1.3 AstraZeneca Plc PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2018-2023)
6.1.4 AstraZeneca Plc PD-1&PD-L1 Immunotherapy Product Portfolio
6.1.5 AstraZeneca Plc Recent Developments/Updates
6.2 BeiGene, Ltd.
6.2.1 BeiGene, Ltd. Corporation Information
6.2.2 BeiGene, Ltd. Description and Business Overview
6.2.3 BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2018-2023)
6.2.4 BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio
6.2.5 BeiGene, Ltd. Recent Developments/Updates
6.3 Bristol-Myers Squibb Company
6.3.1 Bristol-Myers Squibb Company Corporation Information
6.3.2 Bristol-Myers Squibb Company Description and Business Overview
6.3.3 Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Product Portfolio
6.3.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.4 Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
6.4.1 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Corporation Information
6.4.2 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Description and Business Overview
6.4.3 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio
6.4.5 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Recent Developments/Updates
6.5 Eli Lilly & Company
6.5.1 Eli Lilly & Company Corporation Information
6.5.2 Eli Lilly & Company Description and Business Overview
6.5.3 Eli Lilly & Company PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Eli Lilly & Company PD-1&PD-L1 Immunotherapy Product Portfolio
6.5.5 Eli Lilly & Company Recent Developments/Updates
6.6 F. Hoffmann-La Roche Ltd
6.6.1 F. Hoffmann-La Roche Ltd Corporation Information
6.6.2 F. Hoffmann-La Roche Ltd Description and Business Overview
6.6.3 F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2018-2023)
6.6.4 F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Product Portfolio
6.6.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
6.7 GlaxoSmithKline plc
6.6.1 GlaxoSmithKline plc Corporation Information
6.6.2 GlaxoSmithKline plc Description and Business Overview
6.6.3 GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2018-2023)
6.4.4 GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Product Portfolio
6.7.5 GlaxoSmithKline plc Recent Developments/Updates
6.8 Innovent Biologics, Inc.
6.8.1 Innovent Biologics, Inc. Corporation Information
6.8.2 Innovent Biologics, Inc. Description and Business Overview
6.8.3 Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Product Portfolio
6.8.5 Innovent Biologics, Inc. Recent Developments/Updates
6.9 Jiangsu HengRui Medicine Co., Ltd.
6.9.1 Jiangsu HengRui Medicine Co., Ltd. Corporation Information
6.9.2 Jiangsu HengRui Medicine Co., Ltd. Description and Business Overview
6.9.3 Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio
6.9.5 Jiangsu HengRui Medicine Co., Ltd. Recent Developments/Updates
6.10 Merck & Co., Inc.
6.10.1 Merck & Co., Inc. Corporation Information
6.10.2 Merck & Co., Inc. Description and Business Overview
6.10.3 Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Product Portfolio
6.10.5 Merck & Co., Inc. Recent Developments/Updates
6.11 Novartis AG
6.11.1 Novartis AG Corporation Information
6.11.2 Novartis AG PD-1&PD-L1 Immunotherapy Description and Business Overview
6.11.3 Novartis AG PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Novartis AG PD-1&PD-L1 Immunotherapy Product Portfolio
6.11.5 Novartis AG Recent Developments/Updates
6.12 Pfizer Inc.
6.12.1 Pfizer Inc. Corporation Information
6.12.2 Pfizer Inc. PD-1&PD-L1 Immunotherapy Description and Business Overview
6.12.3 Pfizer Inc. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Pfizer Inc. PD-1&PD-L1 Immunotherapy Product Portfolio
6.12.5 Pfizer Inc. Recent Developments/Updates
6.13 Regeneron Pharmaceuticals Inc.
6.13.1 Regeneron Pharmaceuticals Inc. Corporation Information
6.13.2 Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Description and Business Overview
6.13.3 Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Product Portfolio
6.13.5 Regeneron Pharmaceuticals Inc. Recent Developments/Updates
6.14 Sanofi S.A.
6.14.1 Sanofi S.A. Corporation Information
6.14.2 Sanofi S.A. PD-1&PD-L1 Immunotherapy Description and Business Overview
6.14.3 Sanofi S.A. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Sanofi S.A. PD-1&PD-L1 Immunotherapy Product Portfolio
6.14.5 Sanofi S.A. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 PD-1&PD-L1 Immunotherapy Industry Chain Analysis
7.2 PD-1&PD-L1 Immunotherapy Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 PD-1&PD-L1 Immunotherapy Production Mode & Process
7.4 PD-1&PD-L1 Immunotherapy Sales and Marketing
7.4.1 PD-1&PD-L1 Immunotherapy Sales Channels
7.4.2 PD-1&PD-L1 Immunotherapy Distributors
7.5 PD-1&PD-L1 Immunotherapy Customers
8 PD-1&PD-L1 Immunotherapy Market Dynamics
8.1 PD-1&PD-L1 Immunotherapy Industry Trends
8.2 PD-1&PD-L1 Immunotherapy Market Drivers
8.3 PD-1&PD-L1 Immunotherapy Market Challenges
8.4 PD-1&PD-L1 Immunotherapy Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global PD-1&PD-L1 Immunotherapy Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global PD-1&PD-L1 Immunotherapy Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global PD-1&PD-L1 Immunotherapy Market Competitive Situation by Manufacturers in 2024
Table 4. Global PD-1&PD-L1 Immunotherapy Sales (Units) of Key Manufacturers (2018-2023)
Table 5. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Manufacturers (2018-2023)
Table 6. Global PD-1&PD-L1 Immunotherapy Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global PD-1&PD-L1 Immunotherapy Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market PD-1&PD-L1 Immunotherapy Average Price (US$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of PD-1&PD-L1 Immunotherapy, Industry Ranking, 2021 VS 2024 VS 2023
Table 10. Global Key Manufacturers of PD-1&PD-L1 Immunotherapy, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of PD-1&PD-L1 Immunotherapy, Product Type & Application
Table 12. Global Key Manufacturers of PD-1&PD-L1 Immunotherapy, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global PD-1&PD-L1 Immunotherapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PD-1&PD-L1 Immunotherapy as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global PD-1&PD-L1 Immunotherapy Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Table 17. Global PD-1&PD-L1 Immunotherapy Sales by Region (2018-2023) & (Units)
Table 18. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Region (2018-2023)
Table 19. Global PD-1&PD-L1 Immunotherapy Sales by Region (2024-2034) & (Units)
Table 20. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Region (2024-2034)
Table 21. Global PD-1&PD-L1 Immunotherapy Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Region (2018-2023)
Table 23. Global PD-1&PD-L1 Immunotherapy Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Region (2024-2034)
Table 25. North America PD-1&PD-L1 Immunotherapy Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 26. North America PD-1&PD-L1 Immunotherapy Sales by Country (2018-2023) & (Units)
Table 27. North America PD-1&PD-L1 Immunotherapy Sales by Country (2024-2034) & (Units)
Table 28. North America PD-1&PD-L1 Immunotherapy Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America PD-1&PD-L1 Immunotherapy Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe PD-1&PD-L1 Immunotherapy Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 31. Europe PD-1&PD-L1 Immunotherapy Sales by Country (2018-2023) & (Units)
Table 32. Europe PD-1&PD-L1 Immunotherapy Sales by Country (2024-2034) & (Units)
Table 33. Europe PD-1&PD-L1 Immunotherapy Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe PD-1&PD-L1 Immunotherapy Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific PD-1&PD-L1 Immunotherapy Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 36. Asia Pacific PD-1&PD-L1 Immunotherapy Sales by Region (2018-2023) & (Units)
Table 37. Asia Pacific PD-1&PD-L1 Immunotherapy Sales by Region (2024-2034) & (Units)
Table 38. Asia Pacific PD-1&PD-L1 Immunotherapy Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific PD-1&PD-L1 Immunotherapy Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America PD-1&PD-L1 Immunotherapy Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 41. Latin America PD-1&PD-L1 Immunotherapy Sales by Country (2018-2023) & (Units)
Table 42. Latin America PD-1&PD-L1 Immunotherapy Sales by Country (2024-2034) & (Units)
Table 43. Latin America PD-1&PD-L1 Immunotherapy Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America PD-1&PD-L1 Immunotherapy Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa PD-1&PD-L1 Immunotherapy Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 46. Middle East & Africa PD-1&PD-L1 Immunotherapy Sales by Country (2018-2023) & (Units)
Table 47. Middle East & Africa PD-1&PD-L1 Immunotherapy Sales by Country (2024-2034) & (Units)
Table 48. Middle East & Africa PD-1&PD-L1 Immunotherapy Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa PD-1&PD-L1 Immunotherapy Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global PD-1&PD-L1 Immunotherapy Sales (Units) by Type (2018-2023)
Table 51. Global PD-1&PD-L1 Immunotherapy Sales (Units) by Type (2024-2034)
Table 52. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2018-2023)
Table 53. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2024-2034)
Table 54. Global PD-1&PD-L1 Immunotherapy Revenue (US$ Million) by Type (2018-2023)
Table 55. Global PD-1&PD-L1 Immunotherapy Revenue (US$ Million) by Type (2024-2034)
Table 56. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2018-2023)
Table 57. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2024-2034)
Table 58. Global PD-1&PD-L1 Immunotherapy Price (US$/Unit) by Type (2018-2023)
Table 59. Global PD-1&PD-L1 Immunotherapy Price (US$/Unit) by Type (2024-2034)
Table 60. Global PD-1&PD-L1 Immunotherapy Sales (Units) by Application (2018-2023)
Table 61. Global PD-1&PD-L1 Immunotherapy Sales (Units) by Application (2024-2034)
Table 62. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2018-2023)
Table 63. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2024-2034)
Table 64. Global PD-1&PD-L1 Immunotherapy Revenue (US$ Million) by Application (2018-2023)
Table 65. Global PD-1&PD-L1 Immunotherapy Revenue (US$ Million) by Application (2024-2034)
Table 66. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Application (2018-2023)
Table 67. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Application (2024-2034)
Table 68. Global PD-1&PD-L1 Immunotherapy Price (US$/Unit) by Application (2018-2023)
Table 69. Global PD-1&PD-L1 Immunotherapy Price (US$/Unit) by Application (2024-2034)
Table 70. AstraZeneca Plc Corporation Information
Table 71. AstraZeneca Plc Description and Business Overview
Table 72. AstraZeneca Plc PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 73. AstraZeneca Plc PD-1&PD-L1 Immunotherapy Product
Table 74. AstraZeneca Plc Recent Developments/Updates
Table 75. BeiGene, Ltd. Corporation Information
Table 76. BeiGene, Ltd. Description and Business Overview
Table 77. BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 78. BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Product
Table 79. BeiGene, Ltd. Recent Developments/Updates
Table 80. Bristol-Myers Squibb Company Corporation Information
Table 81. Bristol-Myers Squibb Company Description and Business Overview
Table 82. Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Product
Table 84. Bristol-Myers Squibb Company Recent Developments/Updates
Table 85. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Corporation Information
Table 86. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Description and Business Overview
Table 87. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Product
Table 89. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Recent Developments/Updates
Table 90. Eli Lilly & Company Corporation Information
Table 91. Eli Lilly & Company Description and Business Overview
Table 92. Eli Lilly & Company PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Eli Lilly & Company PD-1&PD-L1 Immunotherapy Product
Table 94. Eli Lilly & Company Recent Developments/Updates
Table 95. F. Hoffmann-La Roche Ltd Corporation Information
Table 96. F. Hoffmann-La Roche Ltd Description and Business Overview
Table 97. F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Product
Table 99. F. Hoffmann-La Roche Ltd Recent Developments/Updates
Table 100. GlaxoSmithKline plc Corporation Information
Table 101. GlaxoSmithKline plc Description and Business Overview
Table 102. GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Product
Table 104. GlaxoSmithKline plc Recent Developments/Updates
Table 105. Innovent Biologics, Inc. Corporation Information
Table 106. Innovent Biologics, Inc. Description and Business Overview
Table 107. Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Product
Table 109. Innovent Biologics, Inc. Recent Developments/Updates
Table 110. Jiangsu HengRui Medicine Co., Ltd. Corporation Information
Table 111. Jiangsu HengRui Medicine Co., Ltd. Description and Business Overview
Table 112. Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Product
Table 114. Jiangsu HengRui Medicine Co., Ltd. Recent Developments/Updates
Table 115. Merck & Co., Inc. Corporation Information
Table 116. Merck & Co., Inc. Description and Business Overview
Table 117. Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Product
Table 119. Merck & Co., Inc. Recent Developments/Updates
Table 120. Novartis AG Corporation Information
Table 121. Novartis AG Description and Business Overview
Table 122. Novartis AG PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 123. Novartis AG PD-1&PD-L1 Immunotherapy Product
Table 124. Novartis AG Recent Developments/Updates
Table 125. Pfizer Inc. Corporation Information
Table 126. Pfizer Inc. Description and Business Overview
Table 127. Pfizer Inc. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 128. Pfizer Inc. PD-1&PD-L1 Immunotherapy Product
Table 129. Pfizer Inc. Recent Developments/Updates
Table 130. Regeneron Pharmaceuticals Inc. Corporation Information
Table 131. Regeneron Pharmaceuticals Inc. Description and Business Overview
Table 132. Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 133. Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Product
Table 134. Regeneron Pharmaceuticals Inc. Recent Developments/Updates
Table 135. Sanofi S.A. Corporation Information
Table 136. Sanofi S.A. Description and Business Overview
Table 137. Sanofi S.A. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 138. Sanofi S.A. PD-1&PD-L1 Immunotherapy Product
Table 139. Sanofi S.A. Recent Developments/Updates
Table 140. Key Raw Materials Lists
Table 141. Raw Materials Key Suppliers Lists
Table 142. PD-1&PD-L1 Immunotherapy Distributors List
Table 143. PD-1&PD-L1 Immunotherapy Customers List
Table 144. PD-1&PD-L1 Immunotherapy Market Trends
Table 145. PD-1&PD-L1 Immunotherapy Market Drivers
Table 146. PD-1&PD-L1 Immunotherapy Market Challenges
Table 147. PD-1&PD-L1 Immunotherapy Market Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of PD-1&PD-L1 Immunotherapy
Figure 2. Global PD-1&PD-L1 Immunotherapy Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global PD-1&PD-L1 Immunotherapy Market Share by Type in 2024 & 2034
Figure 4. PD-1 Inhibitors Product Picture
Figure 5. PD-L1 Inhibitors Product Picture
Figure 6. Global PD-1&PD-L1 Immunotherapy Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 7. Global PD-1&PD-L1 Immunotherapy Market Share by Application in 2024 & 2034
Figure 8. Non-Small Cell Lung Cancer
Figure 9. Esophageal Cancer
Figure 10. Urothelial Carcinoma
Figure 11. Hepatocellular Carcinoma
Figure 12. Small Cell Lung Cancer
Figure 13. Others
Figure 14. Global PD-1&PD-L1 Immunotherapy Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 15. Global PD-1&PD-L1 Immunotherapy Market Size (2018-2034) & (US$ Million)
Figure 16. Global PD-1&PD-L1 Immunotherapy Sales (2018-2034) & (Units)
Figure 17. Global PD-1&PD-L1 Immunotherapy Average Price (US$/Unit) & (2018-2034)
Figure 18. PD-1&PD-L1 Immunotherapy Report Years Considered
Figure 19. PD-1&PD-L1 Immunotherapy Sales Share by Manufacturers in 2024
Figure 20. Global PD-1&PD-L1 Immunotherapy Revenue Share by Manufacturers in 2024
Figure 21. The Global 5 and 10 Largest PD-1&PD-L1 Immunotherapy Players: Market Share by Revenue in 2024
Figure 22. PD-1&PD-L1 Immunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2024
Figure 23. Global PD-1&PD-L1 Immunotherapy Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Figure 24. North America PD-1&PD-L1 Immunotherapy Sales Market Share by Country (2018-2034)
Figure 25. North America PD-1&PD-L1 Immunotherapy Revenue Market Share by Country (2018-2034)
Figure 26. U.S. PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 27. Canada PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 28. Europe PD-1&PD-L1 Immunotherapy Sales Market Share by Country (2018-2034)
Figure 29. Europe PD-1&PD-L1 Immunotherapy Revenue Market Share by Country (2018-2034)
Figure 30. Germany PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 31. France PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 32. U.K. PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 33. Italy PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 34. Russia PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 35. Asia Pacific PD-1&PD-L1 Immunotherapy Sales Market Share by Region (2018-2034)
Figure 36. Asia Pacific PD-1&PD-L1 Immunotherapy Revenue Market Share by Region (2018-2034)
Figure 37. China PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 38. Japan PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 39. South Korea PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 40. India PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 41. Australia PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 42. Taiwan PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 43. Indonesia PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 44. Thailand PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 45. Malaysia PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 46. Philippines PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 47. Latin America PD-1&PD-L1 Immunotherapy Sales Market Share by Country (2018-2034)
Figure 48. Latin America PD-1&PD-L1 Immunotherapy Revenue Market Share by Country (2018-2034)
Figure 49. Mexico PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 50. Brazil PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 51. Argentina PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 52. Middle East & Africa PD-1&PD-L1 Immunotherapy Sales Market Share by Country (2018-2034)
Figure 53. Middle East & Africa PD-1&PD-L1 Immunotherapy Revenue Market Share by Country (2018-2034)
Figure 54. Turkey PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 55. Saudi Arabia PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 56. UAE PD-1&PD-L1 Immunotherapy Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 57. Global Sales Market Share of PD-1&PD-L1 Immunotherapy by Type (2018-2034)
Figure 58. Global Revenue Market Share of PD-1&PD-L1 Immunotherapy by Type (2018-2034)
Figure 59. Global PD-1&PD-L1 Immunotherapy Price (US$/Unit) by Type (2018-2034)
Figure 60. Global Sales Market Share of PD-1&PD-L1 Immunotherapy by Application (2018-2034)
Figure 61. Global Revenue Market Share of PD-1&PD-L1 Immunotherapy by Application (2018-2034)
Figure 62. Global PD-1&PD-L1 Immunotherapy Price (US$/Unit) by Application (2018-2034)
Figure 63. PD-1&PD-L1 Immunotherapy Value Chain
Figure 64. PD-1&PD-L1 Immunotherapy Production Process
Figure 65. Channels of Distribution (Direct Vs Distribution)
Figure 66. Distributors Profiles
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed